Evidence map›Paper›PMID 25869535›Full record

ArticleOrganic & biomolecular chemistry2015

Triazolophostins: a library of novel and potent agonists of IP3 receptors.

Amol M Vibhute, Vera Konieczny, Colin W Taylor, Kana M Sureshan

Open access · hybridAbstract read
In one paragraph

Article in Organic & biomolecular chemistry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.7field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. d-Journal of medicinal chemistry · 2020
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Amol M VibhuteSchool of Chemistry, Indian Institute of Science Education and Research, Thiruvananthapuram, Kerala-695016, India. kms@iisertvm.ac.in.
Vera Konieczny
Colin W Taylor
Kana M Sureshan
Indian Institute of Science Education and Research Thiruvananthapuram · INLawn Tennis Association · GBUniversity of Cambridge · GB

Funding

Biotechnology and Biological Sciences Research CouncilWellcome Trust 101844
6 · The paper itself

Abstract

IP3 receptors are channels that mediate the release of Ca(2+) from the intracellular stores of cells stimulated by hormones or neurotransmitters. Adenophostin A (AdA) is the most potent agonist of IP3 receptors, with the β-anomeric adenine contributing to the increased potency. The potency of AdA and its stability towards the enzymes that degrade IP3 have aroused interest in AdA analogs for biological studies. The complex structure of AdA poses problems that have necessitated optimization of synthetic conditions for each analog. Such lengthy one-at-a-time syntheses limit access to AdA analogs. We have addressed this problem by synthesizing a library of triazole-based AdA analogs, triazolophostins, by employing click chemistry. An advanced intermediate having all the necessary phosphates and a β-azide at the anomeric position was reacted with various alkynes under Cu(i) catalysis to yield triazoles, which upon deprotection gave triazolophostins. All eleven triazolophostins synthesized are more potent than IP3 and some are equipotent with AdA in functional analyses of IP3 receptors. We show that a triazole ring can replace adenine without compromising the potency of AdA and provide facile routes to novel AdA analogs.

Indexed as

AdenosineAnimalsCalciumCell LineChickensHumansInositol 1,4,5-Trisphosphate ReceptorsMolecular Docking SimulationSmall Molecule LibrariesStructure-Activity RelationshipTriazolesadenophostin AAdenosineCalciumInositol 1,4,5-Trisphosphate ReceptorsSmall Molecule LibrariesTriazoles

Identifiers

PMID25869535
PMCPMC4533600
OpenAlexW2058409310

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.